NCT07017023 Combined Blood Pressure Medication and Activity Scheduling for Low Mood
| NCT ID | NCT07017023 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Oxford |
| Condition | Emotional Processing |
| Study Type | INTERVENTIONAL |
| Enrollment | 76 participants |
| Start Date | 2025-07-08 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 76 participants in total. It began in 2025-07-08 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study explores the effects of 7-day losartan (50mg) versus placebo with brief behavioural activation on emotional processing in young volunteers low in positive mood
Eligibility Criteria
Inclusion Criteria: * Willing and able to provide informed consent * Aged 18-65 years * Self-reported low levels of positive mood * Sufficient written and spoken English skills to understand study procedures * Normal or corrected to normal vision and hearing * Access to a computer and reliable internet connection Exclusion Criteria: * Antidepressant treatment or medication in last three months * Currently receiving cognitive-behavioural therapy with behavioural activation * History of psychosis or bipolar disorder * History of substance dependence * Use of illegal drugs in last 3 months * First-degree relative with history of psychosis or bipolar disorder * Current or past hospitalisation for mental health reasons * BDI-II score \>30 * Judged to be currently at clinical risk of suicide * Past suicide attempt * CNS-medication last 6 weeks (including in another study) * Severely underweight or overweight in a manner that renders them unsuitable for the study in the opinion of the study medic * Current blood pressure or other heart medication * Diagnosis of intravascular fluid depletion or dehydration * History of angioedema * Impaired kidney function (based on self-report) * Very low blood pressure following established definitions (at least three consecutive measurements of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90/60 mmHg (in accordance with established standard definitions: https://www.nhs.uk/cond...-pressure-hypotension/) * Current diagnosis of a developmental disorder (e.g. ADHD, Tourette's syndrome, severe learning disability) according to self-report, where in the opinion of the study team such difficulties would likely interfere with compliance or task performance * Current diagnosis of a neurological disorder (e.g. epilepsy, MS) according to self-report * Lifetime history of systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may put the participant at risk when participating, or may influence compliance or task performance * Pregnancy (urine pregnancy test during Baseline Visit), breast feeding or plans to become pregnant during study participation * Heavy use of cigarettes (smoke \> 20 cigarettes per day) * Severe lactose intolerance (due to losartan containing some lactose monohydrate)
Contact & Investigator
Andrea Reinecke, PhD
PRINCIPAL INVESTIGATOR
University of Oxford
Frequently Asked Questions
Who can join the NCT07017023 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Emotional Processing. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07017023 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07017023 currently recruiting?
Yes, NCT07017023 is actively recruiting participants. Contact the research team at andrea.reinecke@psych.ox.ac.uk for enrollment information.
Where is the NCT07017023 trial being conducted?
This trial is being conducted at Oxford, United Kingdom.
Who is sponsoring the NCT07017023 clinical trial?
NCT07017023 is sponsored by University of Oxford. The principal investigator is Andrea Reinecke, PhD at University of Oxford. The trial plans to enroll 76 participants.